Young-PEARL Phase II Study of Palbociclib, Exemestane, and Leuprolide vs Capecitabine in Premenopausal Women With HR+/HER2- MBC

May 31 - June 4, 2019; Chicago, Illinois
Palbociclib in combination with endocrine therapy and OFS prolonged PFS vs single-agent capecitabine in premenopausal women with HR+/HER2- MBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 7, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Novartis Pharmaceuticals Corporation
Puma Biotechnology

Related Content

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Jamie Carroll, MSN on managing adverse events and promoting adherence to CDK4/6 and PI3K inhibitors, from Clinical Care Options (CCO)

Robert T. Carroll, PhD(c), RN, ACRN Released: July 26, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings